Voyager Therapeutics is a clinical-stage gene therapy company focused on developing treatments for patients suffering from severe neurological diseases. Co.'s pipeline consists of programs for severe neurological indications, including Parkinson's disease; Huntington's disease; a monogenic form of amyotrophic lateral sclerosis; Friedreich's ataxia; tau-related diseases including Alzheimer's disease, frontotemporal dementia, and progressive supranuclear palsy; and alpha-synuclein related diseases including Parkinson's disease and other synucleinopathies. Co. is engaged in the ongoing conduct and review of preclinical studies for its Huntington's disease program, VY-HTT01. The VYGR stock yearly return is shown above.
The yearly return on the VYGR stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2019 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the VYGR annual return calculation with any dividends reinvested as applicable (on ex-dates).
|